Applications

Regenerative Medicine

Novel Regenerative Medicine Approaches

To date, most human in vivo cell clinical and tissue engineering studies have employed adult stem and progenitor cells. However, initial clinical trials utilizing pluripotent stem cells are underway, and these cells may eventually emerge as a more tractable source of human material. iCell® and MyCell® products are being employed in a number of regenerative medicine applications:

  • Regenerative medicine compound screening: Due to their biological relevance and compatibility with high-throughput screening paradigms, iCell and MyCell products enable identification of novel regenerative compounds
  • Tissue engineering: iCell and MyCell products can be used to bioengineer implantable devices, reconstitute decellularized organs, and manufacture organs using 3D bioprinting
  • Allogeneic and autologous cell applications: iPS cell technology may one day be used for allogeneic and autologous cell applications with the added benefit of being able to introduce a genetically corrected disease mutation in this context

CDI’s cellular reprogramming technologies, intellectual property portfolio, and manufacturing capabilities have broad applicability to the design, development, and manufacturing of future cell-based therapies. Translation of these therapeutic approaches to the clinic will require HLA-matched banks of iPS cells generated under good manufacturing practice (GMP) conditions, a project currently underway in a CDI partnership with Waisman Biomanufacturing.

Contact us to learn more about these exciting advances.

Genetic Manipulation of Endothelial Cells

The ability to interrogate and monitor gene expression is critical to understanding biological pathways that underlie normal and pathogenic cellular function.

Learn More
Print
Description Available Resources

Genetic Manipulation of Endothelial Cells

Discovery, Regenerative Medicine, Toxicity

The ability to interrogate and monitor gene expression is critical to understanding biological pathways that underlie normal and pathogenic cellular function. CDI has worked to evaluate a wide range of genetic manipulation tools to enable the development of assays using its endothelial cells.

3D Spheroid Cell Culture

3D spheroid culture of iCell Hepatocytes 2.0 for enhanced functional maturity and prolonged culturability.

Learn More
Print
Description Available Resources

3D Spheroid Cell Culture

Discovery, Regenerative Medicine, Toxicity

Moving beyond traditional static-plated culture yields a more liver-like environment for hepatocyte assays and generates more predictive biology in vitro. The combination of iPSC technology with advanced culture techniques offers advantages over existing models.  Conditions developed allow for a tunable spheroid size with maintenance of viability and put the control over engineered tissue in the hands of the user. This novel workflow allows for the generation of iCell® Hepatocytes 2.0 microtissues in low-attachment plates.

Pageof 2